Recombinant activated factor VII

Paediatric Anaesthesia

Volumn 16, Issue 9, 2006, Pages 907-909

  Chin, Christopher ^a,b  

^a EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANGIONEUROTIC EDEMA; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CANCER; CARDIOVASCULAR DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; FEVER; FIBRINOLYSIS; GLANZMANN DISEASE; HEART INFARCTION; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; INJECTION SITE PAIN; LUNG EMBOLISM; NAUSEA; OBESITY; PHARMACODYNAMICS; PRIORITY JOURNAL; RASH; REVIEW; STROKE; THROMBIN TIME; THROMBOELASTOGRAPHY; VOMITING;

BLOOD PLATELETS; FACTOR VIIA; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS;

EID: 33747069089     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2006.02034.x     Document Type: Review

References (30)

1. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 1836-1841.
2. Hedner U, Bjoern S, Bernvil SS et al. Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis 1989; 19: 335-343.
3. Poon MC, Demers C, Jobin F et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94: 3951-3953.
4. Brown JB, Emerick KM, Whitington PF et al. Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr 2003; 37: 268-272.
5. Razon Y, Erez E, Vidne B et al. Recombinant factor VIIa (Novoseven) as a hemostatic agent after surgery for congenital heart disease. Pediatr Anesth 2005; 15: 235-240.
6. Wittenstein B, Ng C, Ravn H et al. Recombinant factor VIIa for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med 2005; 6: 473-476.
7. de Santiago J, Martinez-Garcia E, Giron J et al. Prophylactic recombinant factor VIIa administration to an infant with congenital systemic juvenile xanthogranuloma. Pediatr Anesth 2006; 16: 974-976.
8. Chuansumrit A, Wangruangsatid S, Lektrakul Y et al. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis 2005; 16: 549-555.
9. Monroe DM, Hoffman M, Allen GA et al. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost 2000; 26: 373-377.
10. Roberts H. Is factor VIIa a general hemostatic agent? Yes. J Thromb Haemost 2004; 2: 1691-1694.
11. Monroe DM, Roberts HR. Mechanism of action of high-dose factor VIIa: points of agreement and disagreement. Arterioscler Thromb Vasc Biol 2003; 23: 8-9. discussion 10.
12. Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1: 1138-1139.
13. Thabut D, de Franchis R, Bendtsen F et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A [abstract]. J Hepatol 2003; 38: 13.
14. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
15. Levy JH, Fingerhut A, Brott T et al. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion 2006; 46: 919-933.
16. Andrew M, Vegh P, Johnston M et al. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005.
17. Telgt DS, Macik BG, McCord DM et al. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res 1989; 56: 603-609.
18. Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Semin Hematol 2004; 41: 20-24.
19. Lindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-648.
20. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 2000; 26: 385-391.
21. Villar A, Aronis S, Morfini M et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 352-359.
22. Cooper HA, Jones CP, Campion E et al. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001; 7: 517-522.
23. Kenet G, Lubetsky A, Luboshitz J et al. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 1: 450-455.
24. He S, Blomback M, Jacobsson Ekman G et al. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 1: 1215-1219.
25. Wolberg AS, Monroe DM, Roberts HR et al. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood 2003; 101: 3008-3013.
26. Odeyemi IAO, Friedrich PW, Levi M. Economic impact of recombinant activated factor VII in the control of bleeds associated with abdominal prostatectomy. J Med Econ 2004; 7: 107-115.
27. Martinowitz U, Kenet G, Lubetski A et al. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002; 49: S15-S20.
28. Dutton RP, Hess JR, Scalea TM. Recombinant factor VIIa for the control of hemorrhage: early experience in critically ill trauma patients. Can J Clin Anaesth 2003; 5: 184-188.
29. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb 2002; 32(Suppl. 1): 41-46.
30. Meng ZH, Wolberg AS, Monroe DM III et al. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55: 886-891.